Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea

被引:27
作者
Lam, Jamie C. M. [1 ]
Tan, Kathryn C. B. [1 ]
Lai, Agnes Y. K. [1 ]
Lam, David C. L. [1 ]
Ip, Mary S. M. [1 ,2 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Univ Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China
关键词
Advanced glycation end-products; Insulin sensitivity; Obstructive sleep apnoea; Non-diabetic men; CPAP treatment; Severity of sleep disordered breathing; OXIDATIVE STRESS; TOLERANCE-TEST; ENDPRODUCTS; RECEPTOR; GLYCOSYLATION; GLYCOXIDATION; INFLAMMATION; DYSFUNCTION; ACTIVATION; RESISTANCE;
D O I
10.1016/j.sleep.2011.07.015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Patients with diabetes mellitus are known to have increased serum levels of advanced glycation end-products (AGEs), and this is also associated with insulin resistance. This study aimed to investigate the relationship between serum AGEs and insulin sensitivity in non-diabetic subjects with obstructive sleep apnoea (OSA). Methods: Adult males with no known comorbidities were recruited from the sleep clinic of a university teaching hospital. They underwent overnight in-laboratory polysomnography. Fasting blood was taken to measure serum AGE and plasma glucose levels. Insulin sensitivity was estimated using the short insulin tolerance test. Results: In total, 105 subjects with a mean age of 43.5 (standard deviation [SD] 9.2) years, mean body mass index of 27.1 (SD 4.0) kg/m(2), and median apnoea-hypopnoea index (AHI) of 17 (interquartile range 5-46) were analysed. Serum AGE levels were significantly higher in subjects with OSA (AHI >= 5), compared with those without OSA (AHI <5) (3.9 [SD 1.2] vs. 3.2 [SD 0.8] mu g/ml, respectively; P = 0.037) after adjusting for confounders. AGE levels were positively correlated with AHI (r = 0.318, P = 0.001), but not with insulin sensitivity. AGE levels decreased in subjects with moderate-to-severe USA who received continuous positive airway pressure (CPAP) treatment for three months (n = 18, P = 0.017). Conclusions: Serum AGE levels correlate with AHI in non-diabetic adult males. This relationship cannot be explained by insulin sensitivity. Supporting the hypothesis of a direct relationship between AHI and AGEs, AGE levels were found to decline with CPAP therapy. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 47 条
[1]   Advanced glycation endproducts: what is their relevance to diabetic complications? [J].
Ahmed, N. ;
Thornalley, P. J. .
DIABETES OBESITY & METABOLISM, 2007, 9 (03) :233-245
[2]   THE SHORT INSULIN TOLERANCE-TEST FOR DETERMINATION OF INSULIN SENSITIVITY - A COMPARISON WITH THE EUGLYCEMIC CLAMP [J].
AKINMOKUN, A ;
SELBY, PL ;
RAMAIYA, K ;
ALBERTI, KGMM .
DIABETIC MEDICINE, 1992, 9 (05) :432-437
[3]   Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts [J].
Al-Abed, Y ;
Bucala, R .
BIOCONJUGATE CHEMISTRY, 2000, 11 (01) :39-45
[4]  
Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc19-S002, 10.2337/dc12-S064, 10.2337/dc23-S002, 10.2337/dc09-S062, 10.2337/dc18-S002]
[5]   Advanced glycation end products and the kidney [J].
Bohlender, JM ;
Franke, S ;
Stein, G ;
Wolf, G .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (04) :F645-F659
[6]  
BONNET MH, 1992, SLEEP, V15, P526
[7]   ESTIMATES OF INVIVO INSULIN ACTION IN MAN - COMPARISON OF INSULIN TOLERANCE-TESTS WITH EUGLYCEMIC AND HYPERGLYCEMIC GLUCOSE CLAMP STUDIES [J].
BONORA, E ;
MOGHETTI, P ;
ZANCANARO, C ;
CIGOLINI, M ;
QUERENA, M ;
CACCIATORI, V ;
CORGNATI, A ;
MUGGEO, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (02) :374-378
[8]   ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGING [J].
BROWNLEE, M .
ANNUAL REVIEW OF MEDICINE, 1995, 46 :223-234
[9]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[10]  
Bucala R, 1992, Adv Pharmacol, V23, P1